HOPA 2025 Complete Bundle On-Demand

UAN#: 0465-0000-25-008-H01-P

Presenter:

• Madeline Ochs, PharmD, BCOP

Session Description:

This session will provide an overview of recently approved treatments and agents in the pipeline for the treatment of hemophilia, including ultra-long half-life factor VIII, non-factor therapy, and gene therapy. As a result of the expanding treatment armamentarium, prophylaxis considerations are shifting from what is feasible to what is most optimal, with individualization considering patient preferences, adherence, activity level, and efficacy/safety data. This session will provide an update on the various treatment modalities, their clinical efficacy and safety, and clinical pearls that can be used as considerations to guide optimal therapy selection.

Learning Objectives:

1. Review the historical treatment paradigm for hemophilia A and B
2. Describe the mechanisms of action of newly approved agents and those in the pipeline for the treatment of hemophilia A and B
3. Interpret safety and efficacy data for newly approved agents
4. Apply primary literature and patient-specific characteristics to the selection of treatment for patients with hemophilia A and B

UAN#: 0465-0000-25-018-H99-P

Presenters:

• Amber Cipriani, PharmD, BCOP
• Mark Zangardi, PharmD, BCOP, MS

Session Description:

In this session, the presenters will provide a background on the scientific and technological aspects of circulating tumor DNA (ctDNA) testing; reviewing current applications for ctDNA testing in cancer care; appraise recent clinical trial data on the use of ctDNA testing in various settings; discuss limitations, practical challenges, and unanswered questions related to ctDNA testing in routine clinical practice; and provide insight into future directions surrounding ctDNA testing across the cancer care continuum. The session will focus on how pharmacists can be involved in the selection and interpretation of ctDNA test results to inform treatment decisions and improve patient care.

Learning Objectives:

1. Describe circulating tumor DNA (ctDNA) testing technologies
2. Compare the benefits and limitations of ctDNA testing with tissue-based testing
3. Interpret the data using ctDNA to monitor for response or resistance to treatment in advanced cancer
4. Evaluate examples of the use of ctDNA to guide therapeutic decisions prior to and after local therapy in early stage solid tumors
5. Summarize the evidence for cancer early detection assays utilizing ctDNA technology

UAN#: 0465-0000-25-030-H01-P

Presenter:

• Bianka Patel, PharmD, BCOP, CPP

Session Description:

The treatment landscape of chronic lymphocytic leukemia (CLL) has evolved significantly over the last several years. This session will provide an overview of noteworthy updates, including novel combinations in the front-line setting and newer therapies such as the non-covalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy, lisocabtagene maraleucel in the relapsed/refractory setting. Subsequent therapy for relapsed/refractory CLL is based on the type of front-line therapy received and initial response. However, the selection and sequencing of therapies in the relapsed/refractory setting has become increasingly challenging due to the growing number of available options. This session will critically evaluate the data for newer regimens in the relapsed/refractory setting and elucidate the role of each within the treatment paradigm of CLL.

Learning Objectives:

1. Review current guidelines for the treatment of CLL
2. Summarize the data derived from novel treatment strategies for frontline management of CLL
3. Examine the use of the non-covalent BTK inhibitor, pirtobrutinib, and CAR T-cell therapy in relapsed/refractory CLL
4. Design a treatment algorithm for relapsed/refractory CLL

UAN#: 0465-0000-25-036-H01-P

Presenters:

• Jennifer Collins, PharmD, BCOP

Session Description:

This presentation will focus on analyzing the limitations of the current prophylaxis and treatment agents for acute GVHD, as well as exploring new options. Clinical trials utilizing novel agents will be described, and their weaknesses and opportunities highlighted. Discussion will include potential therapeutic drug targets, steroid-free treatment options, biomarker utilization, and sequencing of agents in the steroid-refractory setting.

Learning Objectives:

1. Describe the pathophysiology and outcomes associated with acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplant (HSCT)
2. Recognize the limitations of current preventative and treatment strategies
3. Evaluate clinical data for new preventative and treatment strategies
4. Apply novel options for management of acute GVHD based on patient factors

UAN#: 0465-0000-25-041-L01-P

Presenters:

• Sarah Hayward, PharmD, BCOP
• Erin Hickey Zacholski, PharmD, BCOP
• Jennifer MacDonald, PharmD, BCOP
• Jennifer Stagg, PharmD, BCPS

Session Description:

This session will focus on navigating challenging conversations with patients, including discussion of risk vs benefits of therapy, incorporating an individual's goals of care into the conversation, and creating a safe space to develop rapport and trust with patients. Oncology pharmacists are uniquely equipped to understand intent and toxicities of treatment, and explain these in a way that is easy for patients to understand and absorb. An evidence-based framework will be shared to equip pharmacists during these conversations and facilitate shared decision-making. Concepts will be demonstrated with cases. Pharmacists will learn concrete strategies to help patients make the best decision for their care and improve patient outcomes.

Learning Objectives:

1. Define goals of care conversations and shared clinical decision making
2. Describe barriers to serious illness conversations
3. Apply an evidence-based framework for serious illness conversation into patient care conversations
4. Conduct patient care conversations where shared clinical decision making is utilized
5. Incorporate goals of care into patient education for those receiving palliative intent therapy

UAN#: 0465-0000-25-054-H01-P

Presenter:

• Brooke Adams, PharmD, BCOP

Session Description:

This 75-minute BCOP session will focus on the role and development of adoptive cellular therapies (ACT) for solid tumors. It will summarize the challenges faced in the development of ACT for solid tumors, review recent cellular therapy FDA approvals, and lastly discuss future directions of cellular therapies in the solid tumor pipeline.

Learning Objectives:

1. Discuss the role and mechanisms of adoptive cellular therapy for solid tumor malignancies
2. Describe the challenges in the development of cellular therapies for solid tumor malignancies compared to hematologic malignancies
3. Review the adverse event profile, management, and supportive care for tumor infiltrating lymphocytes (TILs)
4. Summarize the role bi-specific T-cell engaging antibodies in solid tumor malignancies
5. Explain the future directions of cellular therapies in solid tumor malignancies

UAN#: 0465-0000-25-060-H01-P

Presenters:

• Caitlin Harper, PharmD, RPH
• Jennifer Piccolo, PharmD, BCOP

Session Description:

Pharmacogenomics is the study of a patient’s genetic profile and the impact on medication metabolism, safety, and efficacy. Application of pharmacogenomics in oncology allows for medication personalization leading to decreased side effect potential and reduction in treatment related mortality.  This session will discuss the application of key genes impacting cancer and supportive care therapies including models for pharmacogenomics implementation and the data supporting pharmacogenomics guided treatment adjustments to improve patient care of both adult and pediatric patients.

Learning Objectives:

1. Recognize drug-gene pairs with evidence-based guidelines relevant to oncology practice
2. Select an appropriate medication and dose based on gene variants
3. Apply pharmacogenomic results in the context of patient specific factors and goals of therapy to a patient care when recommending adjustments in dose for cancer treatment
4. Compare different pharmacogenomics practice models for application in oncology practice
5. Counsel patients on pharmacogenomic testing results and implications on treatment

UAN#: 0465-0000-25-010-H01-P

Presenters:

• Rachel Feaster, PharmD, BCOP, BCPS
• Christy Harris, PharmD, BCOP

Session Description:

This session will detail roles that clinical oncology pharmacists can play in integrative medicine by describing various settings and workflows in which they have already established themselves within multidisciplinary integrative medicine clinics. Clinical pearls regarding supplement interaction evaluation, appropriate resources, and patient counseling points will also be reviewed.

Common supplement interactions with oncology treatment will be discussed via patient cases, with time for panel discussion on individual approach to reviewing supplement safety and effectiveness using available guideline information and clinical trial information when available. Clinical oncology pharmacists will walk away from this session with improved strategies for supplement interaction evaluation and discussion with patients, as well as tools for implementation of a clinical oncology pharmacist in an integrative medicine setting.

Learning Objectives:

1. Describe opportunities for pharmacist involvement in integrative cancer therapy
2. Discuss clinical pearls regarding dietary supplement use while on cancer therapy
3. Review available guidelines and clinical trials that provide recommendations regarding the use of dietary supplements in oncology supportive care
4. Apply recommendations for the concomitant use of dietary supplements with cancer therapy in specific patient scenarios

UAN#: 0465-0000-25-012-H01-P

Dexamethasone vs. Tocilizumab for Management of CRS Related to Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma

Presenter:

• James Davis, PharmD, BCOP

Session Description:

The approval and widespread adoption of eight oncology specific bispecific antibodies (including three in multiple myeloma) has necessitated oncology pharmacists to become experts in the management of common adverse events such as cytokine release syndrome (CRS). Tocilizumab is often preferred for the treatment of bispecific antibody related CRS but is costly and must be administered intravenously. In this session, we present data from six U.S. academic medical centers and compare CRS management strategies with dexamethasone vs tocilizumab in patients receiving teclistamab for treatment of relapsed/refractory multiple myeloma.

Learning Objectives:

1. Summarize differing strategies for the management of cytokine release syndrome in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM).

Evaluating the Impact of Interactive Ambulatory Care Topic Discussions at an Oncology Center

Presenter:

• Abigail Shockley, PharmD, BCOP

Session Description:

This presentation explores the development and implementation of the Ambulatory Shared Pharmacy Student Instruction (ASPSI) program at a large oncology academic medical center. The program was designed to enhance pharmacy students' confidence in managing common ambulatory care conditions, including diabetes mellitus, hypertension, constipation/diarrhea, and anticoagulation, during advanced pharmacy practice experiences (APPE). Given that APPEs in an oncology setting may not provide consistent exposure to these standard ambulatory care issues, this program aimed to bridge that gap through interactive case-based discussions. Survey results demonstrated improvements in student confidence across all topic areas following participation. This session will describe its instructional design, highlight program outcomes, and discuss opportunities for future expansion.

Learning Objectives:

1. Identify various case-based discussion strategies to improve student confidence in managing common ambulatory care conditions during specialized oncology APPEs

Smart Solutions: Leveraging Artificial Intelligence in Investigational Drug Services

Presenters:

• Travis Smith, PharmD, BCPS, MBA, CPPS, CPHQ
• Alan Yee, PharmD

Session Description:

Clinical trials protocols can be hundreds of pages long and often require distillation into department specific documents to implement at an institution. These summaries help carry out study logistics and provide easily accessible information for patient care. However, this work may take several hours for each study and is multiplied by the number of departments the study touches. AI assisted workflows may represent an opportunity to significantly reduce documentation burden and aid pharmacists in providing or expanding services. Here we will present the results from the implementation of an AI-enhanced study summary sheet creation workflow in Investigational Drug Services.

Learning Objectives:

1. Describe the application of a Generative Artificial Intelligence (GenAI) workflow enhancement in Investigational Drug Services (IDS) to reduce documentation burden during clinical trials setup

Impact of Clinically Embedded Oncology Pharmacists on Immune Checkpoint Inhibitor Outcomes

Presenters:

• Mark Wagner, PharmD, BCOP
• Colton Zwart, PharmD, BCOP

Session Description:

This session will describe the implementation of clinically embedded oncology pharmacists in a community oncology practice. This pilot program showed significant improvements in patient education and healthcare utilization with implementation of oncology clinical pharmacists for patients receiving immune checkpoint inhibitors.

Learning Objectives:

1. Describe the impact of embedded pharmacist care on clinical outcomes of patients receiving immune checkpoint inhibitor

UAN#: 0465-0000-25-014-H01-P

Presenter:

• Cassidy Blaiss, PharmD, BCOP

Session Description:

Antibody drug conjugates (ADCs) are not new to oncology pharmacy but their use in gynecologic malignancies over the past several years has quickly evolved to become a common standard of care. This presentation will explore the data behind these new uses and discuss the unique mechanisms and associated toxicities. We will also review ADCs currently being studied in the setting of gynecologic malignancies and their upcoming anticipated approvals. The goal of this session is to provide the HOPA community with information that is both data driven and practical from a real-world experience to better their knowledge and practice approach in this specialty.

Learning Objectives:

1. Describe the key components to an antibody drug conjugate (ADC) with associated mechanism of action
2. Understand the role of ADC agents in the treatment of various gynecologic malignancies
3. Recognize ADC toxicities and appropriate supportive care management for these adverse effects
4. Evaluate ongoing clinical trials of ADCs in gynecologic malignancies

UAN#: 0465-0000-25-016-H04-P

Presenters:

• Kaitlyn Bryson, PharmD, BCOP
• Lisa Modelevsky, PharmD, BCOP

Session Description:

This session will focus on exploring various career advancement models for oncology pharmacists, including career ladders, career lattices, and professional development models. In addition, this session will identify barriers to development and implementation of these types of models and provide tangible tools and resources for clinical pharmacists to start the conversation with institutional leadership. This session will be directed towards clinical oncology pharmacists, but the content will also be applicable to pharmacists in administrative roles.

Learning Objectives:

1. Outline the history of career advancement models and dissatisfiers leading to attrition in clinical pharmacy
2. Describe the concepts of career advancement ladders and lattices in healthcare
3. Predict the role career advancement ladders and lattices may play in addressing increased attrition
4. Develop strategies for creation and implementation of a career advancement program

UAN#: 0465-0000-25-020-H99-P

Presenters:

• Jessica Auten, PharmD, BCOP
• Vineeta Rao, PharmD, BCPS, CPP

Session Description:

Guidance for residency programs to incorporate education, training, and support for oncology pharmacy trainees to learn strategies to mitigate moral distress, compassion fatigue, and coping with death and dying is lacking. This session will highlight the current gaps in training and resources for oncology pharmacists dealing with the stress of caring for patients with life-threatening conditions. A residency training model that incorporates programming to equip oncology pharmacy residents with the skills to navigate the emotional complexities of death and dying in cancer care will be introduced. Novel programmatic and departmental initiatives aimed at improving the emotional health of oncology pharmacists will also be discussed. Strategies that promote effective coping mechanisms and enhance emotional wellness within oncology pharmacy will be provided.

Learning Objectives:

1. Characterize the existing gap in resources and training for oncology pharmacists to manage the unique stressors associated with providing care to patients with life-threatening conditions
2. Describe an innovative oncology pharmacy residency training model to fortify pharmacists against moral distress, mitigate compassion fatigue, and equip them with the skills to navigate the emotional complexities of death and dying in cancer care
3. Discuss novel programmatic and departmental initiatives to improve the emotional health and well-being of both oncology pharmacist trainees and seasoned practitioners
4. Recommend strategies that promote effective coping mechanisms and optimize overall wellness within the educational and professional milieu of oncology pharmacy personnel

UAN#: 0465-0000-25-022-H01-P

Presenter:

• Jordan Snyder, PharmD

Session Description:

With "mountains" of new data, the landscape of multiple myeloma management is changing rapidly. Attendees will gain valuable insights into recent advancements in treatment strategies, including novel therapies and emerging clinical trial data such as PERSEUS and IMROZ. Through debate and integration of challenging, real-world cases, participants will learn how to navigate the intricacies of newly diagnosed and relapsed/refractory multiple myeloma and optimize treatment plans. So, grab your boots and let's scale new heights of the ever-changing terrain of multiple myeloma management.

Learning Objectives:

1. Evaluate patient specific factors to determine whether triplet or quadruplet therapy is appropriate for a patient with newly diagnosed multiple myeloma
2. Identify chimeric antigen receptor T-cell (CAR-T) therapy's use in relapsed/refractory myeloma (RRMM), taking into consideration patient preferences, toxicities, and available efficacy data
3. Discuss risks, including long-term toxicities, associated with CAR-T in earlier lines of therapy
4. Select appropriate BCMA directed therapy based on treatment history, patient's health status, and socioeconomic factors

UAN#: 0465-0000-25-024-H01-P

Tarlatamab-dlle: Pioneering a New Frontier in Small Cell Lung Cancer Treatment

Presenters:

• Simona Armanca, PharmD, BCOP
• Radha Rohatgi, PharmD, BCOP

Session Description:

Tarlatamab-dlle is a first-in-class bispecific DLL3-directed CD3 T-cell engager used in patients with small cell lung cancer who have progressed after platinum-based chemotherapy. Given the limited treatment options for this patient population, administering tarlatamab-dlle poses unique challenges, such as the need for inpatient care during the initial doses due to risks such as Cytokine Release Syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANs). Additionally, the session will address the financial and educational hurdles faced by institutions when incorporating tarlatamab-dlle into their formulary, with an emphasis on managing adverse effects in both inpatient and outpatient settings.

Learning Objectives:

1. Recognize the role of tarlatamab-dlle in therapy and assess strategies for managing its adverse effects
2. Design a comprehensive inpatient/outpatient implementation plan for tarlatamab-dlle, addressing clinical, logistical, and safety considerations

Advances in Neoadjuvant Therapy for Melanoma

Presenter:

• Christine Barrett, PharmD, BCOP

Session Description:

Melanoma is the fifth most common type of cancer in the United States, and although cutaneous melanoma is the least common form of skin cancer, it is associated with the highest mortality rates. While the majority of patients will present with localized disease, relapse rates are as high as 40% within the first two years despite surgical resection and adjuvant therapy. Neoadjuvant administration of systemic therapy has become appealing in melanoma due to several proposed benefits over adjuvant treatment, and has been investigated in multiple recent trials. The purpose of this presentation is to review current guideline recommendations and practice-changing literature, and discuss strategies for neoadjuvant therapy in patients with melanoma.

Learning Objectives:

1. Review primary literature supporting the role of neoadjuvant therapy in melanoma
2. Identify treatment strategies and patients that are appropriate candidates for neoadjuvant therapy

UAN#: 0465-0000-25-026-H01-P

Navigating Immune Checkpoint Inhibitor Use in Solid Organ Transplantation

Presenter:

• Mary Chandran, PharmD, BCPS, BCTXP, CPP

Session Description:

In solid organ transplant recipients (SOTR) with advanced cancers, immune checkpoint inhibitors (ICI) have shown improved cancer outcomes but carry a high risk of transplant allograft rejection. This risk is further complicated by the need for concurrent immunosuppression to prevent rejection, which can impair the immune-mediated antitumor effects of ICIs. Managing immunosuppression in SOTRs with high-risk or advanced cancers (e.g., metastatic SCC, melanoma) requires a careful balance and multidisciplinary approach, levering the expertise of both transplant and oncology teams. Given the high incidence of skin cancers among SOT recipients and the available evidence on ICI use for treating skin cancers in this population, guidance for safely and effectively applying ICI therapy will be extended to support its use in treating other cancers in SOT recipients. Oncology and transplant pharmacists are well positioned to guide ICI therapy in SOTRs, optimizing immunosuppression and monitoring to enhance both cancer outcomes and allograft survival.

Learning Objectives:

1. Describe the risks and benefits of immune checkpoint inhibitor (ICI) therapy in solid organ transplant recipients with advanced cancers, including the potential for allograft rejection
2. Compare strategies to optimize immunosuppression management and monitoring in patients receiving ICIs, promoting collaboration between transplant and oncology teams for allograft survival

Fairness, Access, and Representation at HOPA: Current and Future Directions

Presenters:

• Ashley Chen, PharmD, BCOP
• Eric Chow, PharmD, BCOP, MPH

Session Description:

This session will highlight the transformative DEIB initiatives undertaken by HOPA from the inception of the DEI Taskforce in 2021 to the current work championed by the DEI Advisory Group. We will explore key changes and initiatives implemented over the past few years to enhance diversity and belonging within HOPA, highlight tools developed for our members to deliver equitable care for our diverse patient population, and foster an inclusive culture. As a member-driven organization, we also aim to explore future directions and opportunities so that HOPA members can feel empowered to drive HOPA's DEIB efforts going forward.

Learning Objectives:

1. Review the progress, challenges, and achievements of the DEIB Advisory Group since its inception as a task force in 2021
2. Explore the work of the DEIB Advisory Group and the new opportunities and initiatives that incorporate a DEI lens within and across all aspects of HOPA

UAN#: 0465-0000-25-027-L01-P

Updates in the Management of Myelodysplastic Syndrome

Presenter:

• Jenna Ciervo, PharmD, BCOP

Session Description

Myelodysplastic syndrome (MDS) is a heterogenous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myeloid leukemia (AML). Treatment of MDS is selected based on several factors including a patient's risk, transfusion needs, percent of bone marrow blasts, cytogenetic and mutational profile, comorbidities and candidacy for allogeneic stem cell transplantation (alloHSCT). This presentation will focus on the recent updates in the treatment of MDS including the approval of ivosidenib for isocitrate dehydrogenase 1 (IDH1) mutated, relapsed or refractory MDS and imetelstat for low- to intermediate-risk MDS patients with anemia.

Learning Objectives:

1. Describe the pathophysiology, diagnosis, and risk stratification of MDS
2. Summarize the management strategies for low-, intermediate-, and high-risk MDS and review the safety profile and monitoring for ivosidenib and imetelstat

Managing Congenital Thrombotic Thrombocytopenia Purpura: Turning Tiny Platelets Into Big Wins

Presenter:

• Sara Leidy, PharmD, BCOP

Session Description:

This session will provide an exploration of congenital thrombotic thrombocytopenic purpura (cTTP), a rare thrombotic microangiopathic disorder. Similar to other thrombotic microangiopathies (TMAs) such as acquired TTP and atypical hemolytic uremic syndrome (aHUS), effective management of cTTP is crucial for achieving the best patient outcomes. Given the complexity and cost associated with managing this condition, oncology pharmacists play a vital role in optimizing therapy and supporting hematologists. Join me for a detailed session that equips oncology pharmacists to turn patient situations into "big wins" with the knowledge and tools to effectively manage cTTP, ensuring optimal patient care, outcomes, and stewardship.

Learning Objectives:

1. Discuss the background, presentation, and clinical course for patients diagnosed with congenital thrombotic thrombocytopenia purpura (cTTP)
2. Evaluate the evolution of treatment options for cTTP and their respective advantages and limitations

UAN#: 0465-0000-25-032-H01-P

Presenters:

• Alexis Croffie, PhD, LPC
• Stephen Boateng, PharmD
• Onyebuchi Ononogbu, PharmD, BCOP, MPH

Session Description:

This session will explore the challenges Sickle Cell Disease (SCD) patients face in obtaining effective treatment and pain relief. The presentation will cover the disease's pathophysiology, common clinical manifestations, current treatment modalities, and pain management strategies. It will also examine the barriers patients encounter, including healthcare system limitations, stigma, and provider bias. Through real-world case studies and strategies, the session will provide participants with tools to overcome these challenges, emphasizing the critical role of pharmacists in SCD care.

Learning Objectives:

1. Review the pathophysiology, clinical manifestations, and current treatment modalities of Sickle Cell Disease (SCD)
2. Analyze barriers to effective treatment and pain management and the impact of these barriers on patient outcomes
3. Evaluate strategies to overcome barriers in SCD management
4. Describe the role of the pharmacist in SCD care

UAN#: 0465-0000-25-034-H01-P

Presenter:

• Danielle Roman, PharmD, BCOP

Session Description:

A treatment landscape once dominated by endocrine therapy and chemotherapy has been revolutionized with the addition of novel targeted oral therapies and antibody-drug conjugates. Recent new drug approvals in both endocrine-sensitive and -refractory disease have increased treatment options and improved outcomes in this breast cancer subtype. This session seeks to review guideline recommendations and key clinical trials supporting biomarker testing, treatment selection, and optimal treatment sequencing. Practical strategies to identify and manage adverse effects associated with oral targeted therapies will be discussed. Patient cases will be incorporated to emphasize evidence-based treatment decisions considering specific patient and disease characteristics. Investigational strategies, such as the incorporation of immunotherapy and antibody-drug conjugates in earlier lines of therapy will be addressed.

Learning Objectives:

1. Summarize clinical practice guidelines and key clinical trial data supporting the treatment selection for patients with HR-positive, HER2-negative metastatic breast cancer
2. Evaluate optimal treatment sequencing for this patient population
3. Review adverse effects associated with targeted therapies for HR-positive, HER2-negative metastatic breast cancer
4. Formulate evidence-based treatment recommendations for this patient population

UAN#: 0465-0000-25-038-H99-P

Presenter:

• Jina Yun, PharmD

Session Description:

This session will begin with a presentation focusing on combating menopausal side effects of hormone therapy in breast cancer. We will discuss physiological challenges faced during menopause and evidence-based strategies for managing symptoms with a focus on vasomotor symptoms and genitourinary syndrome. The presentation will explore non-hormonal therapies that are utilized as well as introduce some new therapies that have been approved in this setting. The session will end with a patient panel where participants will be able to hear discussion of real-world experiences with menopausal side effects in breast cancer patients and gain tools to support these patients in navigating these complex issues.

Learning Objectives:

1. Review the definition, incidences, and pathophysiology of menopause
2. Describe common menopausal side effects associated with hormone therapies in breast cancer
3. Evaluate the risk and benefit of systemic estrogen use in breast cancer patients
4. Describe non-hormonal therapies and interventions for management of vasomotor and genitourinary symptoms of menopause
5. Develop a comprehensive care plan by identifying unique needs of breast cancer patients experiencing vasomotor or genitourinary syndrome associated with hormone therapy

UAN#: 0465-0000-25-039-L01-P

Presenters:

• Amanda Cass, PharmD, BCOP, BCPS
• Kevin Chen, PharmD, BCOP, MS, CPP
• Shelby Quinn, PharmD, BCOP
• Mya Tran, PharmD, BCOP

Session Description:

Treatment of EGFR-mutant NSCLC has become increasingly complex. For classically activating mutations (ex19del, L858R), the standard of care was osimertinib monotherapy front-line with platinum doublet chemotherapy upon disease progression in patients with stage IV disease. Recent data have demonstrated benefits for front-line EGFR TKI combinations with either chemotherapy or amivantamab, and emerging subsequent-line options include amivantamab/chemotherapy combination or patritumab deruxtecan. New data has also been published using osimertinib in neoadjuvant, adjuvant, and consolidative settings. Given the lack of comparative data amongst these new regimens, it is imperative to understand the efficacy, safety, and administration of each treatment to ensure the most appropriate therapy is selected based on patient-specific clinical, biologic features, as well as their values and goals surrounding treatment.

Learning Objectives:

1. Outline the latest clinical evidence for treatment of patients with surgically resectable EGFR mutant NSCLC
2. Apply current guideline recommendations and clinical evidence for the treatment of locally advanced or unresectable EGFR mutant NSCLC
3. Assess current clinical evidence for the treatment of metastatic EGFR mutant NSCLC
4. Compare efficacy, toxicity, and administration between the various first and subsequent-line treatment options
5. Explain the treatment landscape following disease progression on osimertinib, including emerging and novel treatment options

UAN#: 0465-0000-25-044-H01-P

Presenter:

• Katelyn Toeniskoetter, PharmD, BCOP

Session Description:

As recognized medication experts, pharmacists play a crucial role in supporting their clinical sites and teams by staying ahead of new developments in therapies. This session will explore novel agents in the pipeline for solid tumors, focusing on those in clinical trials and nearing FDA approval. Pharmacists will gain insight into the mechanisms of action, clinical applications, and safety data of these agents. By understanding the latest advancements, attendees will be equipped to optimize therapy and formulary management, improve patient care, and offer clinical recommendations. Upcoming trials and anticipated data will be highlighted to ensure attendees are prepared to interpret results as they become available. This knowledge will help ensure their teams are ready to integrate innovative treatments as they emerge.

Learning Objectives:

1. Recognize the role pharmacists play in facilitating the adoption of innovative treatments within their teams
2. Identify novel agents in the pipeline for solid tumors
3. Describe the mechanisms of action of novel agents
4. Evaluate the efficacy and safety profiles of emerging solid tumor therapies based on available clinical trial data
5. Apply recent clinical trial data to the treatment of patients with solid tumors

UAN#: 0465-0000-25-046-H01-P

Presenters:

• Bernard Marini, PharmD, BCOP
• Anthony Perissinotti, PharmD, BCOP

Session Description:

The role of maintenance therapy in AML is evolving and remains controversial. While oral azacitidine gained approval based on the QUAZAR study, unanswered questions remain regarding the data and its real-world application. Similarly, conflicting data on FLT3 inhibitors (gilteritinib, sorafenib, midostaurin, quizartinib) in the pre- and post-transplant settings fuel ongoing debates over agent selection, toxicity, and quality of life. Adding to the complexity, the use of IDH1/2 inhibitors in maintenance therapy further complicates the landscape. Finally, the widespread use of azacitidine with venetoclax raises critical questions: should maintenance therapy continue indefinitely, stop after a fixed duration, or depend on MRD status? Join this fun and engaging debate sparring over the optimal use of maintenance therapies in AML patients.

Learning Objectives:

1. Recognize the possible need for maintenance therapy in acute myeloid leukemia (AML), especially in patients at high risk of relapse
2. Appraise the literature regarding maintenance therapies in AML
3. Select an agent for maintenance therapy in AML based on a patient care
4. Compare the current standard of continuous venetoclax-based therapy to alternative approaches, such as fixed-duration treatment or measurable residual disease-guided discontinuation
5. Identify toxicity management strategies for maintenance therapies used in AML

UAN#: 0465-0000-25-048-H01-P

Turning the Tide: Immunotherapy's Promise in the Fight Against Merkel Cell Carcinoma

Presenter:

• Andy Maldonado, PharmD, BCOP

Session Description:

This session will discuss the pathophysiology, epidemiology and prognosis for patients with Merkel cell carcinoma (MCC), a rare but deadly skin cancer. It will explore the role of immunotherapy for the treatment of advanced stage MCC. Key pivotal trials demonstrating the efficacy and safety of avelumab, pembrolizumab, nivolumab, retifanlimab and ipilimumab in the treatment of advanced stage MCC will be reviewed.

Learning Objectives:

1. Describe the pathophysiology, epidemiology, and prognosis for Merkel cell carcinoma
2. Interpret key efficacy and safety data on the use of immunotherapy for the treatment of advanced stage Merkel cell carcinoma

New Updates Integrating Checkpoint Inhibitors Into the Management of Colorectal Cancer

Presenters:

• Charlotte Martin, PharmD, BCOP
• Darla Quevedo, PharmD, BCOP

Session Description:

Colorectal cancers pose significant challenges in oncology due to their aggressive nature, high morbidity and limited treatment options. However, recent advancements in checkpoint inhibitor literature have revolutionized cancer treatment paradigms for patients with DNA mismatch repair deficiency (dMMR) and/or microsatellite instability high (MSI-H) colorectal cancers. Patients with dMMR/MSI-H status colorectal cancers have been shown to have a lack of benefit from standard chemotherapy but demonstrate impressive responses to immunotherapy. This presentation aims to explore the integration of checkpoint inhibitors into the management of colorectal cancers, focusing on current research and clinical applications.

Learning Objectives:

1. Describe immune checkpoint inhibitors place in colorectal cancer therapy
2. Interpret the literature regarding the safety and efficacy of checkpoint inhibitors in treating colorectal cancer

UAN#: 0465-0000-25-050-H03-P

505(b)(2) Drugs: New Chaos for Infusion Centers

Presenters:

• Clayton Irvine, PharmD, MBA, MS
• Scott Soefje, PharmD, BCOP, MBA, FCCP, FHOPA

Session Description:

With CMS recently allowing 505(b)(2) drugs to be identified as sole source drugs with their own HCPCS codes, this creates unique challenges for cancer infusion centers. This session will describe why 505(b)(2) drugs are different than traditional generic drugs, outline the barriers these differences create, and present options to manage these drugs to prevent billing errors and denials from payers.

Learning Objectives:

1. Describe the different FDA drug approval pathways
2. Discuss why 505(b)(2) drugs can create difficulties for infusion center pharmacies

Transforming Excess Into Access: Creation of an Oral Chemotherapy Repository Program

Presenter:

• Julie Kennerly-Shah, PharmD, BCPS, MS, MHA

Session Description:

As oncology pharmacists, you understand the financial burden that high-cost oral chemotherapy drugs impose on patients, with monthly costs averaging $1,000-3,000 for patients with insurance. This strain often leads to medication non-adherence, jeopardizing patient outcomes. This session will guide you in establishing an oral chemotherapy drug repository program at your institution, repurposing unused medications to improve patient access at little to no cost. We’ll cover the legislative groundwork, patient eligibility criteria, safety protocols, and inventory management using technology like EPIC Willow. Our program has saved patients over $2 million since its launch. Join us to explore how to transform excess medications into vital resources for those in need.

Learning Objectives:

1. Define oral chemotherapy repository program
2. Describe the key aspects of repository program

UAN#: 0465-0000-25-052-H01-P

CMV You Never: Practical Issues Regarding Cytomegalovirus Prophylaxis/Management in the HSCT Population

Presenters:

• Alexis Kuhn, PharmD, BCOP
• Jenna Puttkammer, PharmD

Session Description:

The landscape of cytomegalovirus (CMV) prophylaxis and treatment for patients undergoing allogeneic hematopoietic stem cell transplant (HCT) has evolved over the past decade, with emergence of newer therapies such as letermovir and maribavir. Gone are the days of toxic agents like ganciclovir, foscarnet, and cidofovir—or are they? In this lively debate, two faculty (one from a community-based practice, and one from a large academic medical center) will explore practical issues related to the use of CMV-directed therapies in patients undergoing HCT. Attendees will walk away from this session with tangible pearls that will enhance their ability to safely and effectively manage CMV prophylaxis and treatment in their own patients.

Learning Objectives:

1. Identify modalities for CMV prophylaxis and treatment in patients undergoing HSCT
2. Apply clinical trial data and guideline recommendations of anti-CMV therapies for the management of patients undergoing HSCT

Use of Psychedelic Medicines in Oncology and Palliative Care: An Out of This World Lecture

Presenter:

• Andrew Whitman, PharmD, BCOP

Session Description:

This session will provide an introduction to the use of psychedelic medicines in the oncology population for the pharmacist. There is considerable overlap with currently studied indications and our patients suffering from malignancies. These include, but are not limited to, end of life existential suffering, depression, anxiety, PTSD, and other forms of trauma. As of the current date, trials with MDMA, psilocybin, ketamine, and cannabis are ongoing in patients with cancer. There has also been a recent review of MDMA therapy for PTSD that was rejected by a panel of scientific advisors for the FDA. Despite this rejection, the FDA's review of a psychedelic medicine likely will spark interest, support, and improved trial designs in the future.

Learning Objectives:

1. Describe the purported uses, pharmacology, and potential toxicities of select classic psychedelic medicines
2. Review existing studies on the use of psychedelic medicines in patients with cancer and discuss future applications and controversies

UAN#: 0465-0000-25-056-H04-P

Presenters:

• Henry Cao, PharmD, BCPS
• Adam DiPippo, PharmD, BCOP
• Jessica Gao, PharmD
• Grace Martin, PharmD, BCOP

Session Description:

Artificial intelligence (AI) holds great promise to transform healthcare for oncology pharmacists, offering opportunities to improve clinical decision-making, enhance patient care, and decrease the time spent on administrative tasks. However, this rapidly advancing technology is often met with hesitation due to concerns about bias, privacy risks, and the possibility of incorrect conclusions. This session will provide attendees with a foundational understanding of AI terminology, explore some of the possibilities and limitations of current AI systems, and discuss strategies for responsible AI use. Through a panel presentation and discussion with current oncology pharmacists and a machine learning engineer, we will discuss this rapidly evolving healthcare landscape and unveil the future of AI in oncology pharmacy.

Learning Objectives:

1. Define key artificial intelligence (AI)-related terminology and foundational concepts in healthcare
2. Describe the current abilities and limitations of various AI systems for oncology pharmacists
3. Discuss the potential future capabilities of AI for oncology pharmacists
4. Analyze the potential risks and ethical concerns surrounding AI use
5. Examine ways to incorporate AI responsibly into precepting and pharmacy education

UAN#: 0465-0000-25-058-H01-P

Presenters:

• Matthew Newman, PharmD, BCOP, MEHP
• Kyle Zacholski, PharmD, BCOP

Session Description:

The use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has led to remarkable cure rates in low- and intermediate-risk acute promyelocytic leukemia (APL). Patients with high-risk APL are at increased risk for early mortality and lower overall survival. The optimal management of high-risk APL is debated, though it includes a backbone regimen of ATRA and ATO with the addition of idarubicin or gemtuzumab ozogamicin during induction. In this session, the speakers will compare the evidence and rationale supporting the use of idarubicin versus gemtuzumab ozogamicin for high-risk APL, focusing on efficacy, toxicity, survivorship, and financial concerns. Attendees will be able to apply these considerations when managing patients at their respective institutions.

Learning Objectives:

1. Define the clinical presentation and potential complications of newly diagnosed high-risk APL
2. Compare the toxicity profiles (clinical and financial) of anthracyclines and gemtuzumab ozogamicin
3. Interpret evidence supporting treatment regimens for high-risk APL containing anthracyclines
4. Interpret evidence supporting treatment regimens for high-risk APL containing gemtuzumab ozogamicin
5. Select a treatment strategy for a patient with high-risk APL, with a focus on short-term treatment-related toxicities

UAN#: 0465-0000-25-062-H01-P

Challenging Cases: Novel Antiviral Therapies for Treatment of Refractory or Resistant Cytomegalovirus in Pediatric Oncology and Stem Cell Transplant

Presenter:

• Susie Long, PharmD

Session Description:

Pediatric oncology and stem cell transplant (SCT) patients are at high risk for Cytomegalovirus (CMV) infections. CMV infections can become refractory or resistant (r/r) after prolonged antiviral therapy, leading to complications like chemotherapy delays and end-organ dysfunction. Treatment options for r/r CMV in pediatric patients are limited. This session will present challenging cases of r/r CMV in pediatric oncology and SCT patients, highlighting the use of novel antiviral agents such as letermovir and maribavir. Attendees will learn about the efficacy and safety of these medications, as well as their place in therapy, addressing gaps in pediatric-specific guidance for CMV management and focusing on the implications for pediatric pharmacists.

Learning Objectives:

1. Discuss the indications, pediatric pharmacy pearls for administration, and patient monitoring parameters of novel antivirals available for the treatment of resistant/refractory cytomegalovirus in pediatric oncology and stem cell transplant patients
2. Outline a therapeutic approach for treatment of resistant/refractory CMV infection incorporating patient-specific factors, primary literature, and drug properties

Venetoclax in Pediatric and Adolescent Leukemia

Presenter:

• Jessica White, PharmD, BCPPS

Session Description:

While venetoclax is widely used in adults, it is primarily only used in relapsed or refractory leukemia for pediatrics. This presentation will assist in the understanding of how it fits into current therapy and where the latest research is headed. Venetoclax has limited dosage forms which can be a challenge in pediatrics. We will discuss learned pearls to help with administration.

Learning Objectives:

1. Discuss how venetoclax may be used to treat pediatric and adolescent leukemia patients
2. Analyze challenges to using venetoclax in this population

UAN#: 0465-0000-25-064-H99-P

Presenter:

• Jessica Davis, PharmD, BCOP, CPP
• Anupama Mathur, PharmD, BCOP
• Bethany Sibbitt, PharmD, BCOP
• Justine Zuk, PharmD

Session Description:

In 2018, ASHP and HOPA published guidelines on the roles and responsibilities of the pharmacy technician in ambulatory oncology pharmacy. These guidelines identify that while traditional roles have mainly involved compounding and technical activities, there are many changes and initiatives within cancer care that warrant the expanded scope of the technician’s role.  In this panel discussion, three health systems will discuss how they are utilizing pharmacy technicians in their ambulatory oncology clinics,  as well as barriers for technician integration. The primary purpose of this panel session is to serve as a guidance for institutions that are looking to implement or expand the roles of their ambulatory oncology pharmacy technicians.

Learning Objectives:

1. Describe the various roles of pharmacy technicians in ambulatory oncology clinics
2. Identify opportunities and barriers for integrating pharmacy technicians into ambulatory oncology clinics
3. Compare and contrast pharmacy technician roles and responsibilities at three different oncology centers
4. Demonstrate how pharmacy technicians can be used to optimize pharmacist workload and improve efficiency of clinic workflows

UAN#: 0465-0000-25-066-H05-P

Presenter:

• Iman Ahmed, PharmD, BCOP

Session Description:

The purpose of this session is to highlight the influence of social determinants of health on disparities in hematologic malignancies. The presentation will discuss disparities in incidence, treatment, and outcomes apparent among patients with hematologic malignancies. The inequalities that occur due to social determinants of health are grouped into 5 key domains: health care access and quality, education access and quality, social and community context, economic stability, and neighborhood and built environment. The presenters will review underlying biological and non-biological factors causing disparities in patients with hematologic malignancies, as well as explore approaches to address these barriers in clinical practice. The presenters will discuss how social determinants of health play a vital role in achieving healthy equity in oncology.

Learning Objectives:

1. Define social determinants of health (SDOH)
2. Recognize current disparities in hematologic malignancies including inequalities in incidence, treatment, and outcomes
3. Describe the influence of SDOH on inequalities in patients with hematologic malignancies
4. Identify approaches that address barriers to health equity in patients with hematologic malignancies focusing on strategies within SDOH